Clinical Trial Update: Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC [Phase 2]

View source ↗

Summary

Phase 2 trial of Inodiftagene Vixteplasmid (BC-819) in unresponsive non-muscle invasive bladder cancer was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Inodiftagene Vixteplasmid (Inodiftagene Vixteplasmid)

Snippet

Sponsor: Anchiano Therapeutics Israel Ltd. | Conditions: Non-muscle Invasive Bladder Cancer (NMIBC) | Phase 2 | Status: TERMINATED | Results posted: 2020-08-19